The conventional diagnostic pathway for patients with suspected PCa involves serum prostate specific antigen (PSA), digital rectal examination (DRE) and prostate biopsy, either via transrectal ultrasound‐guided (TRUS) or transperineal (TP) approach. The gene discussed is KLK3; the disease is posterior cortical atrophy.